217 related articles for article (PubMed ID: 34320928)
1. Targeted immune epitope prediction to HHLA2 and MAGEB5 protein variants as therapeutic approach to related viral diseases.
Achinko DA; Dormer A; Narayanan M; Norman EF
BMC Immunol; 2021 Jul; 22(1):49. PubMed ID: 34320928
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes.
Paul S; Lindestam Arlehamn CS; Scriba TJ; Dillon MB; Oseroff C; Hinz D; McKinney DM; Carrasco Pro S; Sidney J; Peters B; Sette A
J Immunol Methods; 2015 Jul; 422():28-34. PubMed ID: 25862607
[TBL] [Abstract][Full Text] [Related]
3. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
Murata K; Nakatsugawa M; Rahman MA; Nguyen LT; Millar DG; Mulder DT; Sugata K; Saijo H; Matsunaga Y; Kagoya Y; Guo T; Anczurowski M; Wang CH; Burt BD; Ly D; Saso K; Easson A; Goldstein DP; Reedijk M; Ghazarian D; Pugh TJ; Butler MO; Mak TW; Ohashi PS; Hirano N
Elife; 2020 Apr; 9():. PubMed ID: 32314731
[TBL] [Abstract][Full Text] [Related]
4. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
Robbins PF; El-Gamil M; Li YF; Zeng G; Dudley M; Rosenberg SA
J Immunol; 2002 Nov; 169(10):6036-47. PubMed ID: 12421991
[TBL] [Abstract][Full Text] [Related]
5. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
6. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy.
Bredenbeck A; Losch FO; Sharav T; Eichler-Mertens M; Filter M; Givehchi A; Sterry W; Wrede P; Walden P
J Immunol; 2005 Jun; 174(11):6716-24. PubMed ID: 15905511
[TBL] [Abstract][Full Text] [Related]
7. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K
J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691
[TBL] [Abstract][Full Text] [Related]
8.
Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
[TBL] [Abstract][Full Text] [Related]
9. Epitope distribution in ordered and disordered protein regions. Part B - Ordered regions and disordered binding sites are targets of T- and B-cell immunity.
Pavlović MD; Jandrlić DR; Mitić NS
J Immunol Methods; 2014 May; 407():90-107. PubMed ID: 24726865
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay.
Akiyama Y; Komiyama M; Nakamura Y; Iizuka A; Oshita C; Kume A; Nogami M; Miyata H; Ashizawa T; Yoshikawa S; Kiyohara Y; Yamaguchi K
Cancer Immunol Immunother; 2012 Dec; 61(12):2311-9. PubMed ID: 22707303
[TBL] [Abstract][Full Text] [Related]
11. Epitope distribution in ordered and disordered protein regions - part A. T-cell epitope frequency, affinity and hydropathy.
Mitić NS; Pavlović MD; Jandrlić DR
J Immunol Methods; 2014 Apr; 406():83-103. PubMed ID: 24614036
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Selection of Hepatitis B Virus-Derived T Cell Epitopes for Global Immunotherapy Based on Viral Indispensability, Conservation, and HLA-Binding Strength.
de Beijer MTA; Jansen DTSL; Dou Y; van Esch WJE; Mok JY; Maas MJP; Brasser G; de Man RA; Woltman AM; Buschow SI
J Virol; 2020 Mar; 94(7):. PubMed ID: 31852786
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Gloger A; Ritz D; Fugmann T; Neri D
Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
[TBL] [Abstract][Full Text] [Related]
14. Identification of a new MAGE-A10 antigenic peptide presented by HLA-A*0201 on tumor cells.
Jia ZC; Tian Y; Huang ZM; Wang JX; Fu XL; Ni B; Wu YZ
Cancer Biol Ther; 2011 Feb; 11(4):395-400. PubMed ID: 21124073
[TBL] [Abstract][Full Text] [Related]
15. Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
Zhu S; Van den Eynde BJ; Coulie PG; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Immunother; 2012; 35(9):680-8. PubMed ID: 23090077
[TBL] [Abstract][Full Text] [Related]
16. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.
Kobayashi H; Lu J; Celis E
Cancer Res; 2001 Oct; 61(20):7577-84. PubMed ID: 11606397
[TBL] [Abstract][Full Text] [Related]
17. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of HLA-A*0301 epitopes in HIV-1 gag proteins using a novel approach.
Semeniuk CA; Capina RE; Mendoza MG; Kimani J; Ball TB; Luo M; Plummer FA
J Immunol Methods; 2010 Jan; 352(1-2):118-25. PubMed ID: 19903485
[TBL] [Abstract][Full Text] [Related]
19. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).
Koumantou D; Barnea E; Martin-Esteban A; Maben Z; Papakyriakou A; Mpakali A; Kokkala P; Pratsinis H; Georgiadis D; Stern LJ; Admon A; Stratikos E
Cancer Immunol Immunother; 2019 Aug; 68(8):1245-1261. PubMed ID: 31222486
[TBL] [Abstract][Full Text] [Related]
20. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]